CN107737368B - Hemostatic material and its preparation method and application - Google Patents
Hemostatic material and its preparation method and application Download PDFInfo
- Publication number
- CN107737368B CN107737368B CN201711047605.6A CN201711047605A CN107737368B CN 107737368 B CN107737368 B CN 107737368B CN 201711047605 A CN201711047605 A CN 201711047605A CN 107737368 B CN107737368 B CN 107737368B
- Authority
- CN
- China
- Prior art keywords
- nano
- hemostatic material
- hemostatic
- fiber
- crosslinking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/104—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention provides a kind of hemostatic material and its preparation method and application.The hemostatic material includes nano-fibre cluster, and nano-fibre cluster is derived from the nano-fiber material of crosslinking, nano-fibre cluster using its geometric center as starting point towards three-dimensional space any direction size in 5 μm~500 μ ms；And/or in hemostatic material nano-fibre cluster with median D50The size of expression is between 100 μm -500 μm；Nano-fibre cluster has porous structure, and nano-fibre cluster has the cross structure that formation is mutually overlapped by more nano short fibers；The diameter of nano short fiber is between 1nm~1000nm, and length is at 1000 μm or less；The porosity of hemostatic material is 50%~90%.Hemostatic material of the invention has excellent tissue adhension performance and significant haemostatic effect, excellent tissue adherence can guarantee that material fits closely in hemostasis with the surface of a wound, it prevents from being washed away by blood, significantly improves haemostatic effect, and promote its mutual fusion process with tissue.
Description
Technical field
The present invention relates to a kind of hemostatic materials and its preparation method and application, belong to biomedical materials field.
Background technique
Bio-medical material is a kind of new and high technology material to grow up in the late three decades, wherein hemostatic material also with
The accidents such as traffic accident, serious burn and scald and disaster increase the concern for gradually causing medical field.With modern section
The high speed development of technology, the research of hemostatic material achieve very fast progress, and various novel hemostatic materials continuously emerge, property
Very big promotion can also have been obtained.Currently, common topical hemostatic agent has Fibrin Glue, thrombin powder, gelfoam, collagen
Protein sponge, chitosan sponge, oxycellulose, microfibrillar collagen, alginic acid fibre, zeolite, cyanoacrylate, plant are more
Icing Sugar etc..Haemostatic effect is definite, easy to use, good biocompatibility, can control the bio-medical hemostatic material of degradation rate at
The main object paid close attention to and studied for people.
The form of common hemostatic material includes diversified forms, there is powdery, as fibrin ferment freeze-dried powder, plant polyose powder,
Zeolite powder, microfibrillar collagen powder；There is solution-type, such as cyanoacrylate, chitosan solution；There is liquid-type, but in surface of a wound energy shape
At gel or colloid, such as Fibrin Glue, glutaraldehyde-albumin Bioglue；Have it is membranaceous, such as chitosan film, polylactic acid membrane；Also
Have it is spongy, such as collagen protein sponge, gelfoam, microfibrillar collagen sponge, fibrin patch.The hemostatic material of various forms
Material respectively has its advantage, also has respective application advantage, is mainly selected according to surface of a wound type and clinical treatment mode.
In the prior art, the hemostatic material of powdery is mainly polysaccharide microsphere or starch granules, passes through supercritical ultrasonics technology, wet heating
The technologies such as processing, microwave method, Mechanical Method or enzyme perforation realize more microporous of material surface, promoted material specific surface area and
Hydrophilicity plays molecular sieve in wound surface, and the concentration of coagulation factor is promoted by the moisture in absorption blood, is added
The generation of fast clotting mechanism, to realize anastalsis.But there are poor adhesions for current styptic powder, relatively closely knit, preparation
The problems such as complex process, and need to prepare in advance, waste the time of many rescue hemostasis.
Summary of the invention
Problems to be solved by the invention
The purpose of the present invention is to provide a kind of hemostatic materials, with high-specific surface area, excellent adhesion property and show
The haemostatic effect of work.
Further, hemostatic material of the invention also has high porosity, high water absorbing capacity and good biocompatibility,
And it can rapidly be degraded and absorb by organism.
The solution to the problem
The present invention provides a kind of hemostatic material, and the hemostatic material includes nano-fibre cluster, and the nano-fibre cluster is originated from
In the nano-fiber material of crosslinking,
The nano-fibre cluster using its geometric center as starting point towards three-dimensional space any direction size in 5 μm~500 μ
Within the scope of m；And/or in the hemostatic material nano-fibre cluster with median D50The size of expression 100 μm -500 μm it
Between, preferably between 200 μm -400 μm；
The nano-fibre cluster has porous structure, and the nano-fibre cluster has by more nano short fiber phase interconnections
Connect the cross structure to be formed；The diameter of the nano short fiber is between 1nm~1000nm, and length is at 1000 μm or less；
The porosity of the hemostatic material is 50%~90%, preferably 70%~90%.
Hemostatic material according to the present invention, the specific surface area of the hemostatic material are 4m2/ g~50m2/ g, preferably 10m2/
G~40m2/g。
The heap density of hemostatic material according to the present invention, the hemostatic material is less than 0.06g/cm3, preferably 0.025g/
cm3~0.05g/cm3。
Hemostatic material according to the present invention, the water absorption rate of the hemostatic material are greater than 1500%, preferably 2000%~
Water absorption rate between 3000%.
Hemostatic material according to the present invention, the nano-fiber material be originated from biocompatibility and can organism drop
The polymer material absorbed is solved, the nano-fiber material is interwoven by fiber filament；Preferably, the nano-fiber material is
Coma, fibre bundle or tunica fibrosa.
Hemostatic material according to the present invention, the crosslinking are crosslinking in the presence of crosslinking agent, it is preferable that the crosslinking agent
Mass ratio with the nano-fiber material is 0.01~2:1, preferably 0.1~1:1.
Hemostatic material according to the present invention, the hemostatic material also include drug；Preferably, the drug includes blood coagulation
The combination of one or more of enzyme, coagulation factor, growth factor.
The present invention provides a kind of preparation method of hemostatic material according to the present invention, comprising the following steps:
Electrostatic spinning step: the nano-fiber material is prepared by electrostatic spinning；
Cross-linking step: crosslinking Treatment is carried out to the nano-fiber material in the presence of a crosslinking agent, what is be crosslinked receives
Rice fibrous material；
It shears step: shear treatment being carried out to the nano-fiber material of the crosslinking, obtains formed body；
Sifting step: sieving processing is carried out to the formed body.
The preparation method of hemostatic material according to the present invention, the crosslinking agent include: carbodiimides, N- hydroxysuccinimidyl acyl
The combination of one or more of imines, Geniposide or aldehyde compound,
Preferably, the crosslinking agent includes carbodiimides and n-hydroxysuccinimide, it is highly preferred that the carbonization two
The mass ratio of imines and n-hydroxysuccinimide is 1~4:1.
The preparation method of hemostatic material according to the present invention, the shear treatment include,
Pre- shearing step carries out the nano-fiber material of the crosslinking under the revolving speed of 10000~20000rpm/min
Preliminary shear treatment obtains pre- cutting object, and/or
High speed shear step carries out high speed shear to the pre- cutting object under the revolving speed of 30000~50000rpm/min
Processing.
The preparation method of hemostatic material according to the present invention, the sieving processing are to carry out sieving using the mesh screen of 18 mesh,
Collect the formed body that sieving passes through.
The preparation method of hemostatic material according to the present invention, the preparation method further include,
Step is sheared again: under the revolving speed of 40000~50000rpm/min, the unsanctioned formed body of sieving being carried out again
Secondary shear treatment.
The preparation method of hemostatic material according to the present invention, the shear treatment be in the state of being passed through flowing gas into
Capable.
The preparation method of hemostatic material according to the present invention, between the cross-linking step and shearing step further include: elution
Step and/or freeze-drying step.
The present invention also provides a kind of hemostatic articles, comprising: hemostatic material according to the present invention or hemostatic material of the invention
The hemostatic material that the preparation method of material is prepared.
The effect of invention
Hemostatic material of the invention has excellent tissue adhension performance and significant haemostatic effect, excellent tissue adhension
Performance enough guarantees that material fits closely in hemostasis with the surface of a wound, prevents from being washed away by blood, significantly improves haemostatic effect, and promote
Into the mutual fusion process of itself and tissue.
Further, since hemostatic material has high-specific surface area and high porosity, so as in blood environment
The moisture in blood can be absorbed rapidly, improved effective blood coagulation factor concentration in blood, started the endogenous and external source of body
Property hemostatic mechanism, accelerate the generation of coagulation process, thus realize quick-acting haemostatic powder act on.
Further, hemostatic material of the invention also has good biological property, not only has good bio-compatible
Property, can rapidly be degraded by organism absorbs, and clinical use is convenient, can be used for stopping in trauma care and clinical operation
Blood.
Detailed description of the invention
Fig. 1 is the SEM Electronic Speculum schematic diagram of nano-fibre cluster in the hemostatic material of the embodiment of the present invention 1.
Fig. 2 is the hemostatic material of the embodiment of the present invention 1 and the hemostasis validity comparison diagram of commercial product 1.
Fig. 3 is that the hemostatic material of the embodiment of the present invention 1 is degraded pathology figure in animal body.
Fig. 4 is that commercial product 1 is degraded pathology figure in animal body.
Specific embodiment
Various exemplary embodiments, feature and the aspect of the disclosure are described in detail below with reference to attached drawing.It is dedicated herein
Word " exemplary " mean " be used as example, embodiment or illustrative ".Here as any embodiment illustrated by " exemplary "
It should not necessarily be construed as preferred or advantageous over other embodiments.
In addition, giving numerous details in specific embodiment below in order to which the disclosure is better described.
It will be appreciated by those skilled in the art that without certain details, the disclosure equally be can be implemented.In other example,
Method well known to those skilled in the art, means, equipment and step are not described in detail, in order to highlight the master of the disclosure
Purport.
First embodiment
First embodiment of the invention provides a kind of hemostatic material.The hemostatic material includes nano-fibre cluster, described
Nano-fibre cluster has the cross structure that formation is mutually overlapped by more nano short fibers；The nano-fibre cluster is derived from crosslinking
Nano-fiber material.
Wherein, the nano-fiber material of crosslinking can be obtained by carrying out cross-linking modified processing to nano-fiber material.
Hemostatic material can be by being sheared to obtain to the nano-fiber material being crosslinked.It is clipped while can be formed and receive
Rice staple fiber, so that nano-fibre cluster has the cross structure by the more mutual overlap to form of nano short fiber.
The hemostatic material that present embodiment provides macroscopically is being powdery or graininess, can be by spraying or spraying
Mode is applied on the surface of a wound, and the lacuna type surface of a wound or the narrow surface of a wound are particularly suitable for.
<nano-fiber material>
Nano-fiber material of the invention can be originated from biocompatibility and can organism degradation absorb polymerization
Object material, the more preferably polymer material of good hydrophilic property.For example, polymer material may include collagen
(Collagen), one of chitosan (Chitosan), hyaluronic acid (HA), alginate, cellulose and its derivates or
Two or more combinations.
Nano-fiber material of the invention can be interwoven by fiber filament.Preferably prepared using electrospinning process
Nano-fiber material.The nano-fiber material can be coma, fibre bundle or tunica fibrosa, preferably tunica fibrosa.
The principle of electrostatic spinning is to apply high voltage during electrostatic spinning to polymeric liquid, charge is made to introduce liquid
Body.When the accumulation in liquid to it is a certain amount of when, liquid can spray head formed taylor cone, in the effect of extra electric field power
Under overcome surface tension formed liquid jet, then jet stream is in the common of electrostatic repulsion, Coulomb force (Coulomb) and surface tension
Under effect, polymer jet stream is moved along random coil shape track.Jet stream is stretched by traction in a very short period of time, as solvent is waved
Hair or heat loss, polymer jet stream are formed by curing micrometer/nanometer fiber.During electrostatic spinning, many parameters can be to most
Whole electrospun fibers have an impact, and by control process parameter, can prepare different sizes, form and different structure
Micrometer/nanometer fiber.
During electrostatic spinning of the invention, technological parameter can generate shadow to the nano-fiber material that electrostatic spinning obtains
It rings, by controlling technological parameter, the nano-fiber material of different sizes, form and different structure can be prepared.The present invention
The mode of electrostatic spinning is not required particularly, can be electrostatic spinning mode commonly used in the art.Specifically, this
Polymer material is dissolved in suitable solvent by invention, prepares the spinning solution of polymer material；Then use electrostatic spinning will
Spinning solution is spun into the nano-fiber material being interwoven by fiber filament.Preferably, the nano-fiber material has porous
Structure.
<nano-fiber material of crosslinking>
The nano-fiber material of crosslinking of the invention can be obtained by carrying out cross-linking modified processing to nano-fiber material.
Specifically, cross-linking modified is cross-linking modified in the presence of crosslinking agent, so that it is suitable and uniform to obtain the degree of cross linking
It is crosslinked.
In the present invention, carry out cross-linking modified purpose be in order to make hemostatic material while a large amount of imbibitions, can be very
Good maintenance fibre morphology, the body fluid that will not be absorbed soon are dissolved or are broken up.In addition, since the excessively high degree of cross linking can shadow
Water absorption rate, flexibility etc. are rung, in order to obtain the more suitable degree of cross linking, the mass ratio of crosslinking agent and nano-fiber material in the present invention
For 0.01~2:1, preferably 0.1~1:1.
<nano short fiber>
The diameter of nano short fiber of the invention is between 1nm~1000nm, and length is generally in 10mm hereinafter, can be
8mm is hereinafter, can be in 5mm or less.In general, nanofiber in the narrow sense is Nanowire of the diameter within the scope of 1~100nm
Dimension, sensu lato nanofiber further includes that nano-composite fiber, i.e. zero dimension or monodimension nanometer material are combined with conventional fibre
Traditional fibre.For polymer nanocomposite material fiber, due to its just produced on the scale of 1000nm it is many special
Performance, such as huge surface area, easy surface-functionalized and superior mechanical performance, therefore nanofiber refers to directly in the present invention
Nanofiber of the diameter within the scope of 1~1000nm.
<nano-fibre cluster>
As shown in Figure 1, nano-fibre cluster of the invention has porous structure.Nano-fibre cluster can be by receiving to what is be crosslinked
Rice fibrous material is sheared to obtain.It is clipped to be formed simultaneously nano short fiber, so that nano-fibre cluster has by more nanometers
The cross structure of formation is mutually overlapped between staple fiber.Due to mutually overlapping the cross structure of formation between more nano short fibers
And the size of nano-fibre cluster is smaller, so that nano-fibre cluster is in fluffy state, so as to increase nano-fibre cluster
Specific surface area.
The nano-fibre cluster using its geometric center as starting point towards three-dimensional space any direction size in 5 μm~500 μ
Within the scope of m；Specifically, the nano-fibre cluster can be with by the size of starting point towards three-dimensional space any direction of its geometric center
Between 5 μm~50 μm, can between 5 μm~100 μm, can between 5 μm~200 μm, can 5 μm~250 μm it
Between, can between 5 μm~300 μm, can between 5 μm~350 μm, can between 5 μm~400 μm, can 5 μm~
It, can be between 5 μm~500 μm between 450 μm.
<hemostatic material>
As shown in Figure 1, the hemostatic material includes nano-fibre cluster.Nano-fibre cluster with median in hemostatic material
D50The size of expression is between 100 μm -500 μm, preferably between 200 μm -400 μm.Median D described herein50I.e.
Nano-fibre cluster cumulative particle sizes percentile in hemostatic material reaches partial size corresponding when 50%.
The heap density of the hemostatic material is less than 0.06g/cm3, preferably 0.025g/cm3~0.05g/cm3.Hemostatic material
Heap density it is small, with high loft characteristic and superelevation specific surface area.The porosity of the hemostatic material be 50%~
90%, preferably 70%~90%.The specific surface area of the hemostatic material is 4m2/ g~50m2/ g, preferably 10m2/ g~40m2/
g.The water absorption rate of the hemostatic material is greater than 1500%, and the water absorption rate preferably between 2000%~3000% has high water absorption
Performance.
The heap density having due to state hemostatic material of the invention is small, specific surface area is high, porosity is high and water absorption rate is high
Characteristic can be further improved red blood cell in blood, blood coagulation so as to absorb the moisture in blood rapidly in the bleeding surface of a wound
The concentration of the factor etc. accelerates intrinsic coagulation mechanism, improves haemostatic effect.
Further, hemostatic material of the invention also includes drug.Preferably, the drug includes fibrin ferment, blood coagulation
The combination of one or more of the factor, growth factor.By loading drug, the hemostasis of hemostatic material not only can be improved
Performance is also provided simultaneously with and the performances such as promotes quick healing of cut, prevents adhesion.
Second embodiment
Second embodiment of the present invention provides a kind of preparation method of hemostatic material, comprising the following steps:
Electrostatic spinning step: the nano-fiber material is prepared by electrostatic spinning；
Cross-linking step: crosslinking Treatment is carried out to the nano-fiber material in the presence of a crosslinking agent, what is be crosslinked receives
Rice fibrous material；
It shears step: shear treatment is carried out to the nano-fiber material of the crosslinking；
Sifting step: sieving processing is carried out to the formed body.
Described herein is " crosslinking " and " cross-linking modified " with the same or similar meaning, during " crosslinking ",
It can be accompanied with the Some features of " modification ", in the present invention for simplicity, " crosslinking " replacement " cross-linking modified " can be used.
<electrostatic spinning step>
In the electrostatic spinning step, fibrous raw material is prepared in advance, fibrous raw material is dissolved in suitable solvent, is prepared into
The spinning solution of certain density fibrous raw material.Wherein, the fibrous raw material can be the polymeric material in first embodiment
Material.For the specific concentration of solvent type that forms solution, there is no particular limitation, as long as can satisfy subsequent electrostatic spinning work
The requirement of skill.For example, suitable solvent can be trifluoroethanol, hexafluoroisopropanol, trifluoroacetic acid, cyclohexanone, third
The combination of one or more of ketone, butanone, tetrahydrofuran, chloroform, glacial acetic acid, formic acid, propionic acid or water.
Nano-fiber material needed for adjusting spinning parameter preparation can be passed through during electrostatic spinning.Such as voltage, squeeze
Outflow and electric field reception distance, spinning environment etc..Preferably, heretofore described electrostatic spinning process parameter can be with are as follows: pressure
Power is 10~40kV, and it is 0.1~15mL/h that solution, which squeezes out flow, and electric field reception distance is 5~30cm, spinning environment relative temperature
60% hereinafter, environment temperature is 10~40 DEG C.
Furthermore it is possible to consider to load drug in spinning solution or in electro-spinning process, the drug may include blood coagulation
The combination of one or both of the factor, growth factor etc..The anthemorrhagic performance of material not only can be improved, be also provided simultaneously with promotion
Wound healing, the performances such as prevent adhesion.
<cross-linking step>
In the cross-linking step, selected crosslinking agent include carbodiimides, n-hydroxysuccinimide, Geniposide,
The combination of one or more of aldehyde compound.
In view of crosslinking agent is to organismal toxicity size and cross-linking effect, crosslinking agent can select carbodiimides and/or
N-hydroxysuccinimide.It is according to the invention the study found that can be further improved by using n-hydroxysuccinimide
The cross-linking effect of carbodiimides.Therefore, chemical cross-linking agent is preferably the combination of carbodiimides and n-hydroxysuccinimide.
The mass ratio of the more preferably described carbodiimides and n-hydroxysuccinimide is 1~4:1.
In general, cross-linking modified carry out in the solution, in the present invention not to the solvent of the cross-linking modified processing of progress
It is specifically limited, as long as can satisfy the demand of cross-linking modified reaction.In the present invention, the molten of cross-linking modified processing is carried out
Agent can be the alcohol of different quality ratio and the mixed solution of water.Wherein, alcohol is preferably ethyl alcohol, it is highly preferred that the matter of ethyl alcohol and water
Ratio is measured 70% or more.
It is cross-linking modified to control it is possible to further the dosage of reaction condition, crosslinking agent by adjusting crosslinking Treatment
The case where.Such as crosslinking Treatment temperature, the crosslinking Treatment time, the mass ratio of crosslinking agent and nano-fiber material, crosslinking agent matter
The ratio between amount and the volume of solvent etc..Furthermore it is possible to by regulation crosslinking degree, to meet different wounds or clinical operation to drop
Solve the requirement in period.
Reaction condition in heretofore described cross-linking step can be, and crosslinking Treatment temperature is between 1~50 DEG C, preferably
Between 4~30 DEG C.The crosslinking Treatment time between 1~72h, preferably 6~for 24 hours between.The quality of the chemical cross-linking agent
Mass ratio with nano-fiber material is 0.01~2:1, preferably 0.1~1:1.The quality of chemical cross-linking agent and the volume of solvent it
Than for 0.1~10:100, wherein it is preferred that 1~5:100.Crosslinking degree can be further controlled by controlling above-mentioned reaction condition.
In addition, in the present invention, crosslinking Treatment first can also be carried out to fibrous raw material, then again using electrostatic spinning technique into
Row processing, is preferably first handled using electrostatic spinning technique, then carries out crosslinking Treatment to nano-fiber material.
<shearing step>
In shearing step of the invention, the shear treatment may include pre- shearing step, specifically, the pre- shearing step
Rapid is to carry out preliminary shear treatment to the nano-fiber material of the crosslinking under the revolving speed of 10000~20000rpm/min, is obtained
To pre- cutting object.In general, the processing time of shearing step is 10~60min, preferably 20~30min in advance.By shearing in advance
Processing, cross-linking system can tentatively be shredded obtain uniform platelet-shaped material.
Further, the shear treatment also may include high speed shear step, in the high speed shear step, in order to most
The hemostatic material obtained eventually forms more uniform form, and the revolving speed of high speed shear step and time are more crucial；Specifically, high speed
The revolving speed for shearing step can be in 30000~50000rpm/min, preferably between 30000~40000rpm/min；High speed is cut
The time for cutting step is 10~30min, more preferably 15~20min.
Further, the shear treatment is carried out in the state of being passed through flowing gas.Specifically, the shearing
Processing carries out in a reservoir, and has been passed through flowing gas in the container.The container can be closed or non-closed
's.For example, shear treatment of the invention, which can be, is handled using specific cutter.Cutter can have use
In the container for the nano-fiber material for holding the crosslinking.It can be passed through flowing gas in a reservoir, and then to the crosslinking
Nano-fiber material is sheared.In the nano short fiber obtained after clipped, at least partly nano short fiber mutually overlaps shape
At nano-fibre cluster, and what nano-fibre cluster can be fluffy is distributed in the inner space of the container.
Preferably, cutter of the present invention can be passed through flowing gas by way of inflation into container.It can be continuous
Inflation is also possible to interval and inflates, and can also be the mode of circulation inflatable.Flowing gas in the present invention can be to form convection current
Gas, or form the gas etc. of disturbance.
The material of container of the invention is preferably non-metallic material, such as: the non-metallic materials such as organic glass, tetrafluoroethene
Matter.This is because container is connected to the motor during high speed shear, metal material is easy thermally conductive, and high temperature is easy to make nanofiber
Dissolution denaturation occurs for cluster, to influence the performance of nano-fibre cluster to a certain extent, and then influences the performance of hemostatic material.Cause
This, selects non-metallic material, can be to avoid the performance for influencing hemostatic material.In addition, for the ease of observing shear effect, preferably
Organic glass material.
Due to being passed through flowing gas in shear history, that shears is more uniform, and can be further such that only
Blood material obtains higher fluffy degree, to further increase the specific surface area of hemostatic material.
<sifting step shears step again>
In sifting step in the present invention, sieving processing collects what sieving passed through to carry out sieving using the mesh screen of 18 mesh
Formed body.It to obtaining the suitable nano-fibre cluster of size, i.e., is starting point towards three-dimensional space using the geometric center of nano-fibre cluster
Between any direction size in 5 μm~500 μ ms.
Preparation method of the invention further includes shearing step again；The step of shearing again be 40000~
Under the revolving speed of 50000rpm/min, shear treatment again is carried out to the unsanctioned formed body of sieving.It is suitable further to obtain size
Nano-fibre cluster.Preferably, the time of the shear treatment again is 1~30min, preferably 10~20min.
<elution step, freeze-drying step>
It can also include: elution step and/or freeze-drying step between the cross-linking step and shearing step.
The purpose eluted is the unreacted crosslinking agent of removal.Specifically, the elution step may include: 0~
Eluant, eluent is utilized in a low temperature of 20 DEG C, and the nano-fiber material being crosslinked is eluted by E-test, it is described not with removal
The crosslinking agent of reaction.The eluant, eluent includes the mixed liquor of alcohols and water, preferably includes the mixed liquor of second alcohol and water, more preferably
Ground, the mass fraction of ethyl alcohol is 70% or more in the mixed liquor of second alcohol and water.In addition, eluant, eluent and crosslinking Treatment in the present invention
Employed in solvent may be the same or different.
Further, the alcohol-water solution that can use various concentration in the present invention, is repeatedly washed using E-test
It is de-.Preferably, elution requirement are as follows: eluting temperature is 1~20 DEG C, preferably 4~10 DEG C；Elution time be 0.1~5h, preferably 0.5
~2h is repeated 3~5 times.
The purpose being freeze-dried is the extra solvent and eluant, eluent removed in crosslinking Treatment, is helped to improve simultaneously
The porosity of hemostatic material.The freeze-drying the specific steps are, the nano-fiber material after elution is put into container,
1~3h is pre-chilled at -20~-80 DEG C, then container is transferred in freeze drier and is lyophilized, the temperature of freeze-drying is -10
~40 DEG C, preferably -10~30 DEG C；6~72h of freeze-drying at 1~100pa, preferably 20~40pa vacuum degree, preferably 12~for 24 hours.
By using the hemostatic material that preparation method of the invention is prepared, stop relative to commercially available collagen class microfibre
Blood meal, production and processing technology is more simple, and cost is lower, and the selection source of raw material is more extensive, is more in line with industrial metaplasia
The requirement of production.
Furthermore it is possible to which the nano-fibre cluster sealed package that will be obtained after shearing, carries out at the sterilizing of Co-60 gamma-ray irradiation
Reason.Specifically, the sealed package requires in dry environments, ambient humidity fast packing below 30%；Co-60 gamma-rays
Irradiation dose is 15~30kGY.
It need to only be taken out from the package, be can be used to without preparing in advance when use by hemostatic material prepared by the present invention
The surface of a wound saves valuable rescue time, facilitates and simplifies operation, while product is carried and saved more easy.
Third embodiment
Third embodiment of the present invention also provides a kind of hemostatic article, comprising: first embodiment according to the present invention
The hemostatic material that the preparation method of hemostatic material or the hemostatic material of second embodiment of the present invention is prepared.
Hemostatic article of the invention can be used for when organizing oozing of blood, capillary hemorrhage, parteriole bleeding, lacuna oozing of blood
It hemostasis and repairs, and/or, for burning, the hemostasis and reparation of wound, surgical operation wound, have broad application prospects.?
It, can be by means of assisting mating instrument to be applied to the portions such as lacuna in the case where applying the hemostasis and reparation in lacuna oozing of blood
This product and other commercial product can be rule of thumb combined, such as styptic sponge, hemostatic yarn by the oozing of blood of position or doctor
The products such as cloth, to reach better haemostatic effect.
Hemostatic article of the invention forms adhesion energy in wound surface since hemostatic material has good adhesion property
The preferable gel of power carries out good physics closure and realizes hemostasis by compression.Simultaneously as having superhigh specific surface area and parent
The selection of aqueous polymer material can enable material to have high-hydrophilic.It can be absorbed in blood rapidly in the bleeding surface of a wound
Moisture accelerate intrinsic coagulation mechanism to provide the concentration of red blood cell in blood, coagulation factor etc., improve haemostatic effect.
Embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.It is not specified in embodiment specific
Condition person carries out according to conventional conditions or manufacturer's recommended conditions.Reagents or instruments used without specified manufacturer is
It can be with conventional products that are commercially available.
Embodiment 1
(1) gelatin (Gelatin) is dissolved in hexafluoroisopropanol, wherein the mass concentration of gelatin is 12% (g/mL), is stirred
It mixes dissolution and obtains uniform polymer solution, as spinning solution.The polymer solution is placed in electrostatic spinning syringe,
The rate for adjusting micro-injection pump is 6mL/h, and the voltage for adjusting high pressure generator is 25kV, adjusts the reception distance of reception device
For 10cm, spinning environment relative humidity is set as 40%, and environment temperature is 30 DEG C, carries out electrostatic spinning, passes through high-voltage electrostatic spinning
The nano-fiber material being interwoven by fiber filament and with porous structure is prepared in technology.
(2) in 500mL reactor, 225mL ethanol solution is added, adds 25mL aqueous solution, stirs and evenly mixs, so
After weigh 3.57g carbodiimides and 1.43gN- HOSu NHS is dissolved at normal temperature in above-mentioned ethanol-water solution,
5g nano-fiber material is put into reactor, cross-linking modified, processing 12h, the nanofiber material being crosslinked are carried out at 25 DEG C
Material.
(3) ethanol-water solution that configuration ethyl alcohol mass fraction is 70%, after a period of time 3h is pre-chilled in a low temperature of 4 DEG C,
The nano-fiber material of crosslinking is transferred in the ethanol-water solution that above-mentioned ethyl alcohol mass fraction is 70% and is eluted；Elution
After 1h, it is again transferred in 4 DEG C of the ethanol-water solution that ethyl alcohol mass fraction is 95%；After eluting 1h, ethyl alcohol matter is transferred to
It is eluted in 4 DEG C of the ethanol-water solution that amount score is 70%, elutes 1h.Eluted using E-test, with removal
Unreacted carbodiimides and n-hydroxysuccinimide, are repeated 3 times.
(4) nano-fiber material after elution is put into clean container and 3h is pre-chilled at -80 DEG C, then turn container
It moving in freeze drier and is lyophilized, the temperature that freeze-drying is arranged is that 3h is dried at 10 DEG C, it is then dried at 20 DEG C again for 24 hours,
Vacuum degree is set as 30pa.
(5) it by the nano-fiber material after freeze-drying, is put into high-speed shearing machine, setting revolving speed is 10000rpm/
Min, processing time are 30min, are tentatively sheared, obtain the pre- cutting object of strip；Then it sets revolving speed to
30000rpm/min after handling 20min to the pre- cutting object high speed shear of strip, carries out sieving using the mesh screen of 18 mesh, receives
The formed body that passes through of collection sieving is to get to part nano-fibre cluster.
(6) the larger cluster not by mesh screen is placed again into high-speed shearing machine, setting revolving speed is 40000rpm/min；
The processing time is 10min, obtains part nano-fibre cluster.
(7) the nano-fibre cluster sealed package that will be obtained after shearing carries out at the Co-60 gamma-ray irradiation sterilizing of 25kGY
After reason, hemostasia products are obtained.The electron microscope of single nano-fibre cluster is as shown in Figure 1 in the hemostasia products.
Embodiment 2
(1) fibroin albumen (Silk Fibroin) is dissolved in formic acid, wherein the mass concentration of fibroin albumen is 10%
(g/mL), stirring and dissolving obtains uniform polymer solution, as spinning solution.Polymer solution is placed in electrostatic spinning injection
In device, the rate for adjusting micro-injection pump is 2mL/h, and the voltage for adjusting high pressure generator is 30kV, adjusts connecing for reception device
Receiving distance is 15cm, and spinning environment relative humidity is set as 30%, and environment temperature is 40 DEG C, carries out electrostatic spinning.It is quiet by high pressure
The nano-fiber material being interwoven by fiber filament and with porous structure is prepared in Electrospinning.
(2) in 500mL reactor, 150mL ethanol solution is added, adds 50mL aqueous solution and 4mL glutaraldehyde
Stirred and evenly mixed after solution, 2g nano-fiber material be put into reactor, carried out at 40 DEG C it is cross-linking modified, processing for 24 hours, handed over
The nano-fiber material of connection.
(3) ethanol-water solution that configuration ethyl alcohol mass fraction is 70%, after a period of time 3h is pre-chilled in a low temperature of 4 DEG C,
The nano-fiber material of crosslinking is transferred in the ethanol-water solution that above-mentioned ethyl alcohol mass fraction is 70% and is eluted；Elution
After 1h, it is again transferred in 4 DEG C of the ethanol-water solution that ethyl alcohol mass fraction is 95%；After eluting 1h, ethyl alcohol matter is transferred to
It measures in 4 DEG C of the ethanol-water solution that score is 70%, elutes 1h.It is eluted using E-test, it is unreacted to remove
Glutaraldehyde is repeated 3 times.
(4) nano-fiber material after elution is put into clean container and 3h is pre-chilled at -80 DEG C, then shift container
It is lyophilized into freeze drier, the temperature that freeze-drying is arranged is that 3h is dried at -10 DEG C, is then dried for 24 hours, very at 20 DEG C again
Reciprocal of duty cycle is set as 20pa.
(5) it by the nano-fiber material after freeze-drying, is put into high-speed shearing machine, setting revolving speed is 15000rpm/
Min, processing time are 20min, are tentatively sheared, obtain the pre- cutting object of strip.Then it sets revolving speed to
40000rpm/min after handling 30min to the pre- cutting object high speed shear of strip, carries out sieving using the mesh screen of 18 mesh, receives
The formed body that passes through of collection sieving is to get to part nano-fibre cluster.
(6) the larger cluster not by mesh screen is placed again into high-speed shearing machine, setting revolving speed is 50000rpm/min；
The processing time is 10min, obtains part nano-fibre cluster.
(7) the nano-fibre cluster sealed package that will be obtained after shearing carries out at the Co-60 gamma-ray irradiation sterilizing of 25kGY
After reason, hemostasia products are obtained.
Embodiment 3
(1) polyvinyl alcohol (PVA) is dissolved in purified water, wherein the mass concentration of polyvinyl alcohol is 5% (g/mL), is stirred
It mixes dissolution and obtains uniform polymer solution, as spinning solution.Polymer solution is placed in electrostatic spinning syringe, is adjusted
The rate of micro-injection pump is 2mL/h, and the voltage for adjusting high pressure generator is 30kV, and the reception distance for adjusting reception device is
15cm, spinning environment relative humidity are set as 30%, and environment temperature is 40 DEG C, carries out electrostatic spinning.Pass through high-voltage electrostatic spinning skill
The nano-fiber material being interwoven by fiber filament and with porous structure is prepared in art.
(2) in 500mL reactor, 150mL ethanol solution is added, adds 50mL aqueous solution and 4mL glutaraldehyde
Stirred and evenly mixed after solution, 2g nano-fiber material be put into reactor, carried out at 40 DEG C it is cross-linking modified, processing for 24 hours, handed over
The nano-fiber material of connection.
(3) ethanol-water solution that configuration ethyl alcohol mass fraction is 70%, after a period of time 3h is pre-chilled in a low temperature of 4 DEG C,
The nano-fiber material of crosslinking is transferred in the ethanol-water solution that above-mentioned ethyl alcohol mass fraction is 70% and is eluted；Elution
After 1h, it is again transferred in 4 DEG C of the ethanol-water solution that ethyl alcohol mass fraction is 95%；After eluting 1h, ethyl alcohol matter is transferred to
It measures in 4 DEG C of the ethanol-water solution that score is 70%, elutes 1h.It is eluted using E-test, it is unreacted to remove
Glutaraldehyde is repeated 3 times.
(4) nano-fiber material after elution is put into clean container and 3h is pre-chilled at -80 DEG C, then shift container
It is lyophilized into freeze drier, the temperature that freeze-drying is arranged is that 3h is dried at -10 DEG C, is then dried for 24 hours, very at 20 DEG C again
Reciprocal of duty cycle is set as 20pa.
(5) it by the nano-fiber material after freeze-drying, is put into high-speed shearing machine, setting revolving speed is 10000rpm/
Min, processing time are 25min, are tentatively sheared, obtain the pre- cutting object of strip；Then it sets revolving speed to
50000rpm/min after handling 10min to the pre- cutting object high speed shear of strip, carries out sieving using the mesh screen of 18 mesh, receives
The formed body that passes through of collection sieving is to get to part nano-fibre cluster.
(6) the larger cluster not by mesh screen is placed again into high-speed shearing machine, setting revolving speed is 40000rpm/min；
The processing time is 15min, obtains part nano-fibre cluster.
(7) the nano-fibre cluster sealed package that will be obtained after shearing carries out at the Co-60 gamma-ray irradiation sterilizing of 25kGY
After reason, hemostasia products are obtained.
Embodiment 4
(1) carboxymethyl chitosan (CMCH) is dissolved in the mixed solution of purified water and hexafluoroisopropanol, wherein carboxymethyl
The mass concentration of chitosan is 5% (g/mL), and stirring and dissolving obtains uniform polymer solution, as spinning solution.It will polymerization
Object solution is placed in electrostatic spinning syringe, and the rate for adjusting micro-injection pump is 2mL/h, and the voltage for adjusting high pressure generator is
30kV, the reception distance for adjusting reception device is 15cm, and spinning environment relative humidity is set as 30%, and environment temperature is 40 DEG C, into
Row electrostatic spinning.By high-voltage electrostatic spinning technology, the nanometer being interwoven by fiber filament and with porous structure is prepared
Fibrous material.
(2) in 500mL reactor, 150mL ethanol solution is added, adds 50mL aqueous solution and 4mL glutaraldehyde
Stirred and evenly mixed after solution, 2g nano-fiber material be put into reactor, carried out at 40 DEG C it is cross-linking modified, processing for 24 hours, handed over
The nano-fiber material of connection.
(3) ethanol-water solution that configuration ethyl alcohol mass fraction is 70%, after a period of time 3h is pre-chilled in a low temperature of 4 DEG C,
The nano-fiber material of crosslinking is transferred in the ethanol-water solution that above-mentioned ethyl alcohol mass fraction is 70% and is eluted；Elution
After 1h, it is again transferred in 4 DEG C of the ethanol-water solution that ethyl alcohol mass fraction is 95%；After eluting 1h, ethyl alcohol matter is transferred to
It measures in 4 DEG C of the ethanol-water solution that score is 70%, elutes 1h.It is eluted using E-test, it is unreacted to remove
Glutaraldehyde is repeated 3 times.
(4) nano-fiber material after elution is put into clean container and 3h is pre-chilled at -80 DEG C, then shift container
It is lyophilized into freeze drier, the temperature that freeze-drying is arranged is that 3h is dried at -10 DEG C, is then dried for 24 hours, very at 20 DEG C again
Reciprocal of duty cycle is set as 20pa.
(5) it by the nano-fiber material after freeze-drying, is put into high-speed shearing machine, setting revolving speed is 10000rpm/
Min, processing time are 20min, are tentatively sheared, obtain the pre- cutting object of strip；Then it sets revolving speed to
30000rpm/min after handling 20min to the pre- cutting object high speed shear of strip, carries out sieving using the mesh screen of 18 mesh, receives
The formed body that passes through of collection sieving is to get to part nano-fibre cluster.
(6) the larger cluster not by mesh screen is placed again into high-speed shearing machine, setting revolving speed is 40000rpm/min；
The processing time is 10min, obtains part nano-fibre cluster.
(7) the nano-fibre cluster sealed package that will be obtained after shearing carries out at the Co-60 gamma-ray irradiation sterilizing of 25kGY
After reason, hemostasia products are obtained.
Embodiment 5
(1) hydroxypropyl methyl cellulose (HPMC) material is dissolved in the mixed solution of hexafluoroisopropanol and water, wherein hydroxyl
Propyl methocel mass concentration is 10% (g/mL), and stirring and dissolving obtains uniform polymer solution, as spinning solution.
Simultaneously according to the fibrinogen (coagulation factor) of 20 mass % of hydroxypropyl methyl cellulose be added in above-mentioned polymer solution into
Row dissolution.Polymer solution dissolved with fibrinogen is placed in electrostatic spinning syringe, the speed of micro-injection pump is adjusted
Rate is 5mL/h, and the voltage for adjusting high pressure generator is 38kV, and the reception distance for adjusting reception device is 10cm, spinning environment phase
30% is set as to humidity, environment temperature is 40 DEG C, carries out electrostatic spinning.By high-voltage electrostatic spinning technology, prepare compound solidifying
The nano-fiber material of blood factor being interwoven by fiber filament and there is porous structure.
(2) in 500mL reactor, 160mL ethanol solution is added, adds 40mL aqueous solution and 8mL glutaraldehyde
After solution, and pH value is adjusted to acid (pH < 4), stirs and evenly mixs, 6g nano-fiber material is put into reactor, at 35 DEG C
Carry out cross-linking modified, processing 48h, the nano-fiber material being crosslinked.
(3) ethanol-water solution that configuration ethyl alcohol mass fraction is 70%, after a period of time 3h is pre-chilled in a low temperature of 4 DEG C,
The nano-fiber material of crosslinking is transferred in the ethanol-water solution that above-mentioned ethyl alcohol mass fraction is 70% and is eluted；Elution
After 1h, it is again transferred in 4 DEG C of the ethanol-water solution that ethyl alcohol mass fraction is 95%；After eluting 1h, ethyl alcohol matter is transferred to
It measures in 4 DEG C of the ethanol-water solution that score is 70%, elutes 1h.It is eluted using E-test, it is unreacted to remove
Glutaraldehyde is repeated 3 times.
(4) nano-fiber material after elution is put into clean container and 3h is pre-chilled at -80 DEG C, then shift container
It is lyophilized into freeze drier, the temperature that freeze-drying is arranged is that 3h is dried at 30 DEG C, is then dried for 24 hours, very at 20 DEG C again
Reciprocal of duty cycle is set as 40pa.
(5) it by the nano-fiber material after freeze-drying, is put into high-speed shearing machine, setting revolving speed is 20000rpm/
Min, processing time are 10min, are tentatively sheared, obtain the pre- cutting object of strip；Then it sets revolving speed to
40000rpm/min after handling 30min to the pre- cutting object high speed shear of strip, carries out sieving using the mesh screen of 18 mesh, receives
The formed body that passes through of collection sieving is to get to part nano-fibre cluster.
(6) the larger cluster not by mesh screen is placed again into high-speed shearing machine, setting revolving speed is 40000rpm/min；
The processing time is 15min, obtains part nano-fibre cluster.
(7) the nano-fibre cluster sealed package that will be obtained after shearing carries out at the Co-60 gamma-ray irradiation sterilizing of 25kGY
After reason, hemostasia products are obtained.
Performance test
Median D50Test
Test method: it takes product configuration to be measured at the weak solution of certain mass concentration, uses processor for ultrasonic wave (100W)
By solution decentralized processing 10min, disperse nano-fibre cluster particle, uniformly, solution system reaches certain stable state.Using
2000 laser particle size analyzer of Mastersizer of Malvern company, Britain is tested.Before measurement, laser particle size analyzer
30min need to be preheated in advance.When measurement, firstly, instrument is carried out to light, control measurement background state is normal.It then, will be scattered
Sample disposably pours into sample measuring cell, and rinses residual sample with deionized water and pour into sample cell, clicks " analysis " rapidly,
It carries out sample measurement and saves data.It is tested with the hemostasia products of embodiment 1-5, test result is as shown in table 1.
1 median D of table50Test result
| Sample ID | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Median (μm) | 260 | 480 | 350 | 300 | 200 |
As can be seen from Table 1, in the hemostatic material of the application nano-fibre cluster with median D50The ruler of expression
It is very little between 200 μm -500 μm.
Specific surface area test
Test method: product to be measured is taken to be put into the sample cell of analysis instrument, wherein analysis instrument is quickly full-automatic compares
Surface area and Porosimetry, model U.S. health tower NOVA 4200e.Under the conditions of low temperature (liquid nitrogen bath), lead into sample cell
Enter a certain amount of Adsorbate Gas (N2), determine sample to adsorption molecule according to the variation of absorption front and back gas volume
(N2) adsorbance；The ratio table of solid matter is measured with reference to standard GB/T/T24533-2009-gas absorption BET principle
Area.
The calculation of specific surface area are as follows: be put into the sample in gaseous environment, material surface (extra-granular and inside
The surface area in gap) physical absorption will occur at low temperature.When absorption reaches balance, the adsorbed gas of equilibrium adsorptive pressure is measured
The scale of construction calculates sample mono layer adsorption amount according to BET equation, to calculate the specific surface area of sample.Wherein, BET
Equation are as follows:
In formula:
P --- adsorbate partial pressure, unit Pa；
P0--- adsorbent saturated vapor pressure, unit Pa；
V --- the practical adsorbance of sample, unit cm3；
Vm--- single layer saturated extent of adsorption, unit cm3；
C --- constant relevant to sample adsorption capacity.
It is tested with the hemostasia products of embodiment 1-5, test result is as shown in table 2.
2 specific surface area test result of table
| Sample ID | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Specific surface area (m2/g) | 22.187 | 18.321 | 15.477 | 12.385 | 11.308 |
As can be seen from Table 2, hemostasia products of the invention have very high specific surface area.
Porosity test
Porosity measures as follows: the porosity of porous material is determined with solvent completion method.Since ethyl alcohol holds
It easily infiltrates through without causing Material shrinkage and swelling inside porous material, therefore using ethyl alcohol as reagent.
Test method are as follows: be packed into ethanol solution in the small beaker of 50mL, weigh the hemostasia products for being dried to weight
(quality m1) be soaked in ethyl alcohol, circulation is evacuated to hemostasia products there is no bubble spilling, weighs containing ethyl alcohol and hemostasis
The beaker total weight of product is m2, then the hemostasia products taking-up by inside containing ethyl alcohol, remaining beaker and ethyl alcohol are weighed as
m3, each sample is 3 times parallel, as a result as shown in table 3 below.
Measure porosity P are as follows:
P=(m2-m3-m1)/(m2-m3) × 100%
Wherein: (m2-m3-m1) be hemostasia products hole contained in ethyl alcohol quality；
(m2-m3) it is the hemostasia products gross mass containing ethyl alcohol.
It is tested with the hemostasia products of embodiment 1-5, test result is as shown in table 3.
3 porosity test result of table
| Sample ID | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Porosity % | 90 | 82 | 78 | 64 | 71 |
As can be seen from Table 3, the application hemostasia products have very high porosity.
Saturated water absorption test
Test method: by the sample (m of certain mass1) be placed in culture dish, be added be preheated to (37 ± 1) DEG C 0.9%
Physiological saline, the quality of physiological saline are 40 times of material to be tested.Culture dish is moved into drying box, is protected at (37 ± 1) DEG C
Hold 30min.Sample is taken out with tweezers, dangle 30s, with electronic balance precise m2, it is measured in parallel 3 times.It is obtained by calculation
Saturated water absorption (X), the calculation formula of saturated water absorption (X) are as follows: X=(m2-m1)/m1× 100%.
It is tested with the hemostasia products of embodiment 1-5, test result is as shown in table 4, wherein n is to be measured in parallel number.
4 saturated water absorption test result (n=3) of table
| Sample ID | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Saturated water absorption % | 2812±15 | 2550±10 | 2370±8 | 1951±12 | 1733±10 |
As can be seen from Table 4, the application hemostasia products have very high saturated water absorption.
Heap density measurement
Test method: it is V (cm that material, which is freely fallen into volume,3), quality m1(g) in graduated cylinder, stack material freely
Reach volume, then weighs the overall quality m of graduated cylinder and material2(g), then heap density (g/cm3)=(m2-m1)/V。
It is tested with the hemostasia products of embodiment 1-5, the results are shown in Table 5, wherein n is parallel testing number.
5 heap density measurement result (n=3) of table
| Sample ID | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Heap density (g/cm3) | 0.027±0.001 | 0.016±0.002 | 0.022±0.002 | 0.041±0.003 | 0.033±0.002 |
Hemostasis validity test
Test method: using rabbit liver oozing of blood model, cut off the abdomen rabbit hair, and abdomen is opened in the center of standard, dissociates, exposure liver
It is dirty；The wound of 10 × 10 × 2mm is formed in liver same area；The surface of a wound is cleared up with gauze, is covered with the hemostasia products of identical weight
Lid wound surface, and gelfoam is covered above, 30s is pressed, sponge is removed and observes wound oozing of blood situation.When record hemostasis
Between, evaluation hemostasis validity.
It is tested with product made from the embodiment of the present invention 1 (experimental group), while using reference product (commercial product 1)
As positive control, experimental group and control group parallel group number are n=10.
As a result as shown in Fig. 2, the bleeding stopping period of reference product (commercial product) is 308.8s；The embodiment of the present invention 1 is made
Hemostasia products bleeding stopping period be 135.5s；, there is significant difference in P value=0.03, P value < 0.05.Therefore, production of the invention
Bleeding stopping period of the bleeding stopping period of product significantly less than commercial product.
Degradability test
Test method: using the product of the embodiment of the present invention 1 as test material (experimental group), using commercial product as control
Material (control group).
It is tested using rabbit muscular grafting.The abdomen rabbit hair is cut off, abdomen is opened in the center of standard, cuts skin and muscle, implantation
Material, material weight 0.01g are sutured after fixing, then skin closure is closed, postoperative antibiotic care three days.To setting in advance
After the fixed observation period (postoperative 1W (1 week), postoperative 2W (2 weeks), postoperative 4W (4 weeks)), dissection is photographed to record, and tissue is taken to send disease
Reason analysis, pathological analysis evaluate biological tissue's compatibility of implantation site material.
Pathological examination is shown, as shown in figure 3, hemostasia products of the invention have been degraded completely at 4W (4 weeks).And commercially available production
Product can also see the not degradable absorption of some materials at 4W (4 weeks).Also, the tissue verifying stimulation of experimental group is also below right
According to group.Therefore, hemostatic material of the invention has good tissue biocompatibility.In addition, during experiment, Neng Gouguan
The hemostatic material for observing the application has more excellent adhesion property.
The above embodiment of the present invention be only to clearly illustrate example of the present invention, and not be to the present invention
Embodiment restriction.For those of ordinary skill in the art, it can also make on the basis of the above description
Other various forms of variations or variation.There is no necessity and possibility to exhaust all the enbodiments.It is all of the invention
Made any modifications, equivalent replacements, and improvements etc., should be included in the protection of the claims in the present invention within spirit and principle
Within the scope of.
Claims (26)
1. a kind of hemostatic material, which is characterized in that the hemostatic material includes nano-fibre cluster, and the nano-fibre cluster is derived from
The nano-fiber material of crosslinking,
The nano-fibre cluster using its geometric center as starting point towards three-dimensional space any direction size in 5 μm~500 μm models
In enclosing；And/or in the hemostatic material nano-fibre cluster with median D50The size of expression is between 100 μm -500 μm；
The nano-fibre cluster has a porous structure, and the nano-fibre cluster has and by more nano short fibers mutually overlaps shape
At cross structure；The diameter of the nano short fiber is between 1nm~1000nm, and length is at 1000 μm or less；
The porosity of the hemostatic material is 50%~90%.
2. hemostatic material according to claim 1, which is characterized in that nano-fibre cluster with middle position in the hemostatic material
Partial size D50The size of expression is between 200 μm -400 μm.
3. hemostatic material according to claim 1, which is characterized in that the porosity of the hemostatic material be 70%~
90%.
4. hemostatic material according to claim 1, which is characterized in that the specific surface area of the hemostatic material is 4m2/ g~
50m2/g。
5. hemostatic material according to claim 4, which is characterized in that the specific surface area of the hemostatic material is 10m2/ g~
40m2/g。
6. hemostatic material according to claim 1-5, which is characterized in that the heap density of the hemostatic material is less than
0.06g/cm3。
7. hemostatic material according to claim 6, which is characterized in that the heap density of the hemostatic material is 0.025g/cm3
~0.05g/cm3。
8. hemostatic material according to claim 1-5, which is characterized in that the water absorption rate of the hemostatic material is greater than
1500%.
9. hemostatic material according to claim 8, which is characterized in that the water absorption rate of the hemostatic material 2000%~
Between 3000%.
10. hemostatic material according to claim 1-5, which is characterized in that the nano-fiber material is originated from tool
Have biocompatibility and can organism degradation absorb polymer material, the nano-fiber material by fiber filament interweave and
At.
11. hemostatic material according to claim 10, which is characterized in that the nano-fiber material is coma, fiber
Beam or tunica fibrosa.
12. hemostatic material according to claim 1-5, which is characterized in that the crosslinking is in crosslinking agent have
Under crosslinking.
13. hemostatic material according to claim 12, which is characterized in that the crosslinking agent and the nano-fiber material
Mass ratio is 0.01~2:1.
14. hemostatic material according to claim 13, which is characterized in that the crosslinking agent and the nano-fiber material
Mass ratio is 0.1~1:1.
15. hemostatic material according to claim 1-5, which is characterized in that the hemostatic material also includes medicine
Object.
16. hemostatic material according to claim 15, which is characterized in that the drug includes fibrin ferment, coagulation factor, life
The combination of one or more of the long factor.
17. a kind of preparation method of -16 described in any item hemostatic materials according to claim 1, which is characterized in that including following
Step:
Electrostatic spinning step: the nano-fiber material is prepared by electrostatic spinning；
Cross-linking step: crosslinking Treatment, the Nanowire being crosslinked are carried out to the nano-fiber material in the presence of a crosslinking agent
Tie up material；
It shears step: shear treatment being carried out to the nano-fiber material of the crosslinking, obtains formed body；
Sifting step: sieving processing is carried out to the formed body.
18. the preparation method of hemostatic material according to claim 17, which is characterized in that the crosslinking agent includes: carbonization
The combination of one or more of diimine, n-hydroxysuccinimide, Geniposide or aldehyde compound.
19. the preparation method of hemostatic material according to claim 18, which is characterized in that the crosslinking agent includes carbonization two
Imines and n-hydroxysuccinimide.
20. the preparation method of hemostatic material according to claim 19, which is characterized in that the carbodiimides and N- hydroxyl
The mass ratio of base succinimide is 1~4:1.
21. the preparation method of the described in any item hemostatic materials of 7-20 according to claim 1, which is characterized in that at the shearing
Reason includes,
Pre- shearing step carries out the nano-fiber material of the crosslinking preliminary under the revolving speed of 10000~20000rpm/min
Shear treatment obtains pre- cutting object, and/or
High speed shear step carries out at high speed shear the pre- cutting object under the revolving speed of 30000~50000rpm/min
Reason.
22. the preparation method of the described in any item hemostatic materials of 7-20 according to claim 1, which is characterized in that at the sieving
Reason collects the formed body that sieving passes through to carry out sieving using the mesh screen of 18 mesh.
23. the preparation method of hemostatic material according to claim 22, which is characterized in that the preparation method further includes,
Step is sheared again: under the revolving speed of 40000~50000rpm/min, the unsanctioned formed body of sieving being cut again
Cut processing.
24. the preparation method of the described in any item hemostatic materials of 7-20 according to claim 1, which is characterized in that at the shearing
Reason is carried out in the state of being passed through flowing gas.
25. the preparation method of the described in any item hemostatic materials of 7-20 according to claim 1, which is characterized in that the crosslinking step
Suddenly between shearing step further include: elution step and/or freeze-drying step.
26. a kind of hemostatic article characterized by comprising -16 described in any item hemostatic materials according to claim 1, or
The hemostatic material that the preparation method of the described in any item hemostatic materials of claim 17-25 is prepared.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711047605.6A CN107737368B (en) | 2017-10-31 | 2017-10-31 | Hemostatic material and its preparation method and application |
| PCT/CN2018/095636 WO2019011333A1 (en) | 2017-07-14 | 2018-07-13 | Haemostatic material, haemostatic fibre membrane, and haemostatic product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711047605.6A CN107737368B (en) | 2017-10-31 | 2017-10-31 | Hemostatic material and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107737368A CN107737368A (en) | 2018-02-27 |
| CN107737368B true CN107737368B (en) | 2019-10-15 |
Family
ID=61233194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711047605.6A Active CN107737368B (en) | 2017-07-14 | 2017-10-31 | Hemostatic material and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107737368B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019011333A1 (en) * | 2017-07-14 | 2019-01-17 | 广州迈普再生医学科技股份有限公司 | Haemostatic material, haemostatic fibre membrane, and haemostatic product |
| CN108295319B (en) * | 2018-03-08 | 2021-05-11 | 山东省药学科学院 | Medical nanofiber-reinforced hydrophilic composite material and preparation method and application thereof |
| WO2020220300A1 (en) * | 2019-04-30 | 2020-11-05 | 钟春燕 | Biocellulose fiber, hemostatic dressing comprising said fiber and related application |
| CN113117131B (en) * | 2019-12-31 | 2023-01-03 | 广州迈普再生医学科技股份有限公司 | Nanofiber microsphere material and preparation method and application thereof |
| CN113117133B (en) * | 2019-12-31 | 2023-03-14 | 广州迈普再生医学科技股份有限公司 | Fiber aggregate and preparation method and application thereof |
| CN113117132B (en) * | 2019-12-31 | 2022-11-22 | 广州迈普再生医学科技股份有限公司 | Absorbable expansion type nano short fiber powdery material and preparation method and application thereof |
| CN112807477B (en) * | 2020-12-30 | 2023-03-07 | 广州迈普再生医学科技股份有限公司 | Composite hemostatic material and preparation method thereof |
| CN114681678B (en) * | 2020-12-31 | 2023-04-18 | 广州迈普再生医学科技股份有限公司 | Nanofiber sponge and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102753746A (en) * | 2010-09-14 | 2012-10-24 | 纺织和塑料研究协会图林根研究院 | Highly functional spunbonded fabric made from particle-containing fibres and method for producing same |
| CN106012297A (en) * | 2016-06-30 | 2016-10-12 | 吉林大学 | Method for preparing medical complex fiber three-dimensional structure dressing |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5871234B2 (en) * | 2012-03-23 | 2016-03-01 | 国立研究開発法人物質・材料研究機構 | Method for producing synthetic collagen nanofiber |
-
2017
- 2017-10-31 CN CN201711047605.6A patent/CN107737368B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102753746A (en) * | 2010-09-14 | 2012-10-24 | 纺织和塑料研究协会图林根研究院 | Highly functional spunbonded fabric made from particle-containing fibres and method for producing same |
| CN106012297A (en) * | 2016-06-30 | 2016-10-12 | 吉林大学 | Method for preparing medical complex fiber three-dimensional structure dressing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107737368A (en) | 2018-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107737368B (en) | Hemostatic material and its preparation method and application | |
| CN107376000B (en) | Microfibre state hemostatic material and preparation method thereof and hemostatic article | |
| CN107823693B (en) | Stanch fibre film and preparation method thereof and hemostatic article | |
| Zhong et al. | Electrospinning nanofibers to 1D, 2D, and 3D scaffolds and their biomedical applications | |
| Uppal et al. | Hyaluronic acid nanofiber wound dressing—production, characterization, and in vivo behavior | |
| Pei et al. | Effectively promoting wound healing with cellulose/gelatin sponges constructed directly from a cellulose solution | |
| Hivechi et al. | In vitro and in vivo studies of biaxially electrospun poly (caprolactone)/gelatin nanofibers, reinforced with cellulose nanocrystals, for wound healing applications | |
| Chen et al. | Hierarchical porous nanofibers containing thymol/beta-cyclodextrin: Physico-chemical characterization and potential biomedical applications | |
| CN107693835B (en) | Polyvinyl alcohol/collagen/quaternized chitosan electrostatic spinning composite fiber film and preparation method thereof | |
| CN108348633A (en) | It is compacted stanch fibre cellulose aggregate | |
| Deng et al. | Preparation and characterization of cellulose/flaxseed gum composite hydrogel and its hemostatic and wound healing functions evaluation | |
| US20200330641A1 (en) | Biodegradable graphene oxide biocomposite fibrous membrane, preparation method and uses thereof | |
| CN103505758B (en) | Chitosan-nanofiber hemostatic material and preparation method thereof | |
| CN104548189B (en) | Microballoon and its application in wound hemostasis | |
| CN107519524B (en) | Polycaprolactone/collagen/quaternary ammonium salt electrostatic spinning composite fiber membrane and preparation method thereof | |
| Chen et al. | Bio-inspired hydrogels with fibrous structure: A review on design and biomedical applications | |
| CN104491932A (en) | Drug-loaded nanometer anti-adhesion membrane having core/shell structure and preparation method thereof | |
| CN107469127A (en) | The preparation method of natural polysaccharide derivative/natural polymer composite fibre medical wound dressing | |
| Coelho et al. | Electrospinning technology: designing nanofibers toward wound healing application | |
| CN114344555B (en) | Multifunctional hemostatic material and preparation method thereof | |
| CN110975002A (en) | Hemostatic material for war wounds and preparation method and application thereof | |
| CN104548188B (en) | Hyaluronic acid-nano silver-based dressing and preparation method thereof | |
| CN107737364A (en) | A kind of wound dressing and preparation method thereof | |
| Hu et al. | Fabrication and characterization of chitosan coated braided PLLA wire using aligned electrospun fibers | |
| CN115282319B (en) | Artificial muscle fiber, preparation method thereof and wound healing dressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 510633 Third Floor of Zone E, No. 80 Luanyue Road, Science City, Guangzhou High-tech Industrial Development Zone, Guangzhou, Guangdong Province Applicant after: Guangzhou Maple regenerative medicine Polytron Technologies Inc Address before: 510633 Third Floor of Zone E, No. 80 Luanyue Road, Science City, Guangzhou High-tech Industrial Development Zone, Guangzhou, Guangdong Province Applicant before: Medprin Regenerative Medical Technologies Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |